UPDATE: JPMorgan Downgrades Teva Pharma (TEVA) to Underweight
Tweet Send to a Friend
(Updated - November 14, 2022 5:20 AM EST)
JPMorgan analyst Chris Schott downgraded Teva Pharma (NYSE: TEVA) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Chris Schott downgraded Teva Pharma (NYSE: TEVA) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
